| Name | Title | Contact Details |
|---|
InVision Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
University of Pittsburgh Center for BioSecurity is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
US Fitness is constantly growing and improving the fitness experience, and we want you to be part of this revolution! We want passionate, driven individuals who want to spread health and fitness to their communities and are ready to deliver that Ultima...
Southwest General is a 350-bed, non-profit hospital serving southwestern Cuyahoga, northern Medina and eastern Lorain counties. Founded in 1920 by residents of the surrounding communities, Southwest General has a rich history of community partnership and a deep commitment to the health and well-being of the residents it serves. Southwest General is home to nationally recognized physicians, state-of-the-art technology and a full range of medical, surgical and emergency services, including a Level III trauma center. Additionally, patients and families benefit from an extensive program of social services and support groups that provide mental, emotional and spiritual support. All services at Southwest General are provided with an eye toward excellence and individual attention. This is best expressed in Southwest General`s mission statement: Health is our Passion. Quality is our Focus. Compassion is our Way.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.